{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:00:50Z","timestamp":1787508050020,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFE0116700"],"award-info":[{"award-number":["2022YFE0116700"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372023"],"award-info":[{"award-number":["82372023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172010"],"award-info":[{"award-number":["82172010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403285"],"award-info":[{"award-number":["82403285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114367","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:23:16Z","timestamp":1761668596000},"page":"114367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment"],"prefix":"10.1016","volume":"388","author":[{"given":"Danqi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yini","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengcheng","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114367_bb0005","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2025.114367_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104470","article-title":"Chronotherapy in glioblastoma: state of the art and future perspectives","volume":"89","author":"Petkovi\u0107","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2025.114367_bb0015","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1200\/JCO.2017.73.0119","article-title":"Adult glioblastoma","volume":"35","author":"Alexander","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0020","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.114367_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2025.114367_bb0030","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2025.114367_bb0040","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2025.114367_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286418790452","article-title":"Treatment of glioblastoma in adults","volume":"11","author":"Wick","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jconrel.2025.114367_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585616","article-title":"Glioblastoma immune landscape and the potential of new immunotherapies","volume":"11","author":"Daubon","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002181","article-title":"Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma","volume":"9","author":"Simonds","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.114367_bb0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/neuonc\/noad211","article-title":"Lessons learned from phase 3 trials of immunotherapy for glioblastoma: time for longitudinal sampling?","volume":"26","author":"Chen","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2025.114367_bb0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0070","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114367_bb0075","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2025.114367_bb0080","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114367_bb0085","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2025.114367_bb0090","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.09.014","article-title":"Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers","volume":"495","author":"Davern","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.114367_bb0100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41467-024-44963-3","article-title":"Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114367_bb0115","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3390\/ijms25042071","article-title":"Cell membrane-coated nanoparticles for precision medicine: a comprehensive review of coating techniques for tissue-specific therapeutics","volume":"25","author":"Fern\u00e1ndez-Borbolla","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114367_bb0120","article-title":"Recruiting T-cells toward the brain for enhanced glioblastoma immunotherapeutic efficacy by co-delivery of cytokines and immune checkpoint antibodies with macrophage-membrane-camouflaged nanovesicles","volume":"35","author":"Xu","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114367_bb0125","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.biomaterials.2011.11.018","article-title":"The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles","volume":"33","author":"Xin","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114367_bb0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7150\/thno.47841","article-title":"Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114367_bb0145","article-title":"CD47- and integrin \u03b14\/\u03b21-comodified-macrophage-membrane-coated nanoparticles enable delivery of colchicine to atherosclerotic plaque","volume":"11","author":"Li","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2025.114367_bb0150","doi-asserted-by":"crossref","first-page":"10127","DOI":"10.1021\/acsnano.0c03386","article-title":"Translational nanomedicine boosts anti-PD1 therapy to eradicate orthotopic PTEN-negative glioblastoma","volume":"14","author":"Kinoh","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114367_bb0155","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/BC.2007.061","article-title":"Clinical chemistry reference database for Wistar rats and C57\/BL6 mice","volume":"388","author":"Boehm","year":"2007","journal-title":"Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.114367_bb0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","article-title":"Harnessing innate immunity in cancer therapy","volume":"574","author":"Demaria","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114367_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892543","article-title":"On the prognostic power of tumor-infiltrating lymphocytes - a critical commentary","volume":"13","author":"Elkoshi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41590-019-0577-9","article-title":"The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity","volume":"21","author":"Dan","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114367_bb0180","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2025.114367_bb0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2017.04.008","article-title":"Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer","volume":"57","author":"Galletti","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2025.114367_bb0190","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.biomaterials.2018.04.027","article-title":"Combinational strategy for high-performance cancer chemotherapy","volume":"171","author":"Qin","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114367_bb0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-020-1137-5","article-title":"DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.114367_bb0200","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0205","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114367_bb0210","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1021\/acs.chemrev.3c00062","article-title":"Tumor abnormality-oriented nanomedicine design","volume":"123","author":"Zhou","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.114367_bb0215","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.114367_bb0220","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0225","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114367_bb0230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.2023.41.4_suppl.580","article-title":"Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma","volume":"41","author":"Acoba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0235","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114367_bb0245","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jconrel.2025.114367_bb0255","doi-asserted-by":"crossref","first-page":"1255611","DOI":"10.3389\/fimmu.2023.1255611","article-title":"Immunotherapy: a promising approach for glioma treatment","volume":"14","author":"Yasinjan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114367_bb0260","doi-asserted-by":"crossref","first-page":"11325","DOI":"10.1021\/acsnano.2c04982","article-title":"Pleiotropic immunomodulatory functions of radioactive inactivated bacterial vectors for enhanced cancer radio-immunotherapy","volume":"16","author":"Pei","year":"2022","journal-title":"ACS Nano"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:57:41Z","timestamp":1780822661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"alternative-id":["S0168365925009812"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114367","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114367"}}